HSV vax update is now expected "First quarter 2016 later in January or February time frame.
It is a little dependent on 3rd parties."
In terms of clinical trials this is not a huge delay and the integrity of the studies are paramount to its success. For this reason I believe the team at Admedus are looking out for our interests.
I am excited about the cascade of other announcements coming this year including H1 CC sales update, progression of HPV trials and hoping for a possible partnership deal (instead of another CR). Perhaps even some new tissue engineering applications in the pipeline.
I am long term in this one and enjoy keeping updated with its progress and expect to still be a holder in 2020. Who knows where this can go by then.
HSV vax update is now expected "First quarter 2016 later in...
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$9.10 |
Change
-0.810(8.17%) |
Mkt cap ! $192.3M | |||
| Open | High | Low | Value | Volume |
| $9.50 | $9.77 | $9.01 | $212.2K | 22.63K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 298 | $9.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $9.85 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |